Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. operates as a global diversified pharmaceutical company with business segments spanning gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, and eye health. News related to Bausch Health may cover developments across any of these therapeutic areas, including product approvals, clinical trial results, regulatory actions, and commercial launches. The company's Salix business unit focuses on gastroenterology products, with particular emphasis on treatments for hepatic encephalopathy, irritable bowel syndrome, and other gastrointestinal conditions.
Corporate news may include updates on the company's debt management strategies, as Bausch Health has historically carried significant debt obligations stemming from acquisitions. Financial reporting typically addresses performance across the five business segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Bausch + Lomb eye health business represents a substantial portion of company operations and may generate independent news flow regarding vision care products, contact lenses, ophthalmic pharmaceuticals, and surgical equipment.
Dermatology news through the Ortho Dermatologics business may cover new acne treatments, psoriasis therapies, and other prescription dermatology products. Aesthetic medicine developments from Solta Medical often involve non-invasive cosmetic treatment technologies. Strategic acquisitions represent a key component of Bausch Health's growth strategy, with the company periodically acquiring businesses with complementary products in core therapeutic areas. Patent litigation and intellectual property matters frequently impact pharmaceutical companies, and Bausch Health may face generic competition for key products as patents expire.
Regulatory filings, including SEC reports, clinical trial registrations, and FDA submissions, provide transparency into company operations and pipeline developments. Investors monitor revenue trends across business segments, particularly the gastroenterology franchise which includes high-value products. Generic pharmaceutical competition, international market performance, and research and development progress all contribute to the ongoing narrative around this diversified pharmaceutical enterprise.
Bausch + Lomb, a key eye health business of Bausch Health (NYSE/TSX: BHC), announced the ONE by ONE Recycling program has successfully recycled nearly 27 million used contact lenses and packaging since its 2016 launch. The collaboration with TerraCycle has diverted over 162,000 pounds of waste from the environment. With 5,500 participating optometry practices, the initiative also supports Optometry Giving Sight, donating $10 for every 10 pounds collected. This program showcases Bausch Health's commitment to sustainability and environmental responsibility.
Bausch Health Companies (NYSE/TSX: BHC) and its gastroenterology unit Salix Pharmaceuticals announced their participation in the AASLD annual meeting, scheduled for November 13-16, 2020. Salix will present two posters showcasing rifaximin data, highlighting its significance in treating gastrointestinal diseases. Robert Spurr, president of Salix, emphasized their commitment to advancing research in liver disease. The posters focus on a new water-soluble formulation of rifaximin and factors contributing to overt hepatic encephalopathy in clinical trials.
Bausch Health Companies (NYSE/TSX: BHC) will participate in two upcoming investor conferences. CEO Joseph C. Papa and CFO Paul S. Herendeen will present at the Wolfe Virtual Healthcare Conference on Nov. 19, 2020, at 2:55 p.m. ET. Additionally, they will join the Evercore ISI HealthCONx Conference on Dec. 1, 2020, at 8:50 a.m. ET. Live webcasts and audio archives of these events will be accessible on the company's Investor Relations page. Bausch Health aims to enhance global health through its diverse range of healthcare products.
Bausch Health reported third-quarter 2020 revenues of $2.138 billion, down 3% year-over-year, primarily due to COVID-19 impacts. Net income reached $71 million, a significant recovery from a loss of $49 million in Q3 2019. Adjusted EBITDA was $948 million, up 1%. The Bausch + Lomb/International segment's revenue decreased by 1%, while the Salix segment saw a 10% drop, influenced by product exclusivity losses and pandemic effects. Bausch Health reaffirmed its full-year revenue guidance of $7.80 – $8.00 billion and Adjusted EBITDA of $3.15 – $3.30 billion.
Bausch Health Companies (NYSE/TSX: BHC) announced on October 29, 2020, that the FDA granted Orphan Drug Designation to rifaximin for treating sickle cell disease, which affects around 100,000 Americans. This designation encourages the development of treatments for rare diseases. Early data indicates rifaximin may reduce vaso-occlusive crises in sickle cell patients. The company plans to start a Phase 2 trial in 2021 to evaluate a novel rifaximin formulation for this patient population.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is set to redeem a total of $150 million of its senior notes on Nov. 30, 2020. This includes $100 million of 5.875% Senior Notes and $50 million of 5.50% Senior Notes, all funded through cash generated from operations. This move aims to decrease the company’s debt profile significantly. The redemption notices will be sent to record holders, while payments will be processed via the Depository Trust Company.
Bausch + Lomb has launched the SimplifEYE™ intraocular lens (IOL) delivery system, exclusive to the enVista® MX60PL and MX60PT lenses, marking the first preloaded toric lens available in the United States. This system enhances surgical efficiency and reduces handling risks. The enVista lenses feature a wide range of powers, excellent rotational stability, and StableFlex™ technology for improved optic recovery. This innovation underscores Bausch Health's commitment to meet evolving surgical needs.
Bausch Health Companies (NYSE/TSX: BHC) and Ortho Dermatologics will present nine posters at the virtual Fall Clinical Dermatology Conference from Oct. 29 - Nov. 1, 2020. The presentations include new analyses on ARAZLO™, DUOBRII®, SILIQ®, and pediatric data on JUBLIA®. Bill Humphries, president of Ortho Dermatologics, emphasized their commitment to addressing various skin conditions through research. The conference highlights the latest data on acne and psoriasis treatments, showcasing their extensive dermatology portfolio.
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology unit, Salix Pharmaceuticals, will present 11 scientific posters at the American College of Gastroenterology (ACG) 2020 Virtual Annual Scientific Meeting from October 23-28, 2020. These presentations highlight clinical data across Salix's portfolio, emphasizing their commitment to gastrointestinal health. Key topics include the efficacy of Rifaximin, Plecanatide, Methylnaltrexone, and NER1006. Robert Spurr, president of Salix, expressed enthusiasm for collaboration with healthcare professionals at this significant conference.
Bausch Health has strengthened its focus on myopia research through an exclusive license agreement with BHVI for myopia control contact lenses. This partnership aims to develop lenses that may slow myopia progression in children, addressing a growing global health issue projected to affect 50% of the population by 2050. Earlier, Bausch + Lomb secured another licensing agreement with Eyenovia for a pediatric myopia treatment. CEO Joseph C. Papa emphasizes the commitment to innovative solutions for this increasing ocular disorder.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
